Hemab Therapeutics Holdings, Inc. Common Stock COAG
$31.62
+2.36%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $51.40
- Implied Upside
- +62.6%
- Price Target Range
- $36.00 – $64.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-12 | WedbushDavid Nierengarten |
Maintains | Outperform | $55 → $64 |
| 2026-08-11 | HC Wainwright & Co.Emily Bodnar |
Maintains | Buy | $52 → $60 |
| 2026-07-13 | JefferiesMaury Raycroft |
Maintains | Buy | $39 → $47 |
| 2026-07-13 | WedbushDavid Nierengarten |
Maintains | Outperform | $55 |
| 2026-07-13 | HC Wainwright & Co.Emily Bodnar |
Maintains | Buy | $40 → $52 |
| 2026-06-26 | HC Wainwright & Co.Emily Bodnar |
Reiterates | Buy | $40 |
| 2026-06-17 | HC Wainwright & Co.Emily Bodnar |
Initiates coverage on | Buy | $40 |
| 2026-05-26 | WedbushDavid Nierengarten |
Initiates coverage on | Outperform | $42 |
| 2026-05-26 | JefferiesMaury Raycroft |
Initiates coverage on | Buy | $39 |
| 2026-05-26 | Evercore ISI GroupCory Kasimov |
Initiates coverage on | Outperform | $50 |
| 2026-05-26 | Goldman Sachs Richard Law |
Initiates coverage on | Buy | $36 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $31.62
- Market Cap
- $1.44 billion
- 52-Week Range
- $23.00 – $55.42
- Average Volume
- 552K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.